アジア太平洋地域の遺伝性癌検査市場 – 業界動向と2029年までの予測

アジア太平洋地域の遺伝性癌検査市場の分析と洞察

がんは、細胞の機能を制御する遺伝子の特定の変異によって引き起こされる遺伝病であり、特に細胞の増殖と再生に影響を及ぼします。遺伝性の遺伝子変異は、すべてのがんの約5〜10％の原因です。研究者は、特定の遺伝子の変異を、特定のがんの発症を通じて人々に影響を与える50以上の遺伝性がん症候群に関連付けています。さらに、乳がん症例の約5〜10％は、親から受け継いだ遺伝子変異に関連しています。BRCA1遺伝子とBRCA2遺伝子の違いが優勢です。BRCA1変異を持つ女性の生涯乳がんリスクは約72％ですが、BRCA2変異を持つ女性のリスクは約69％です。したがって、がんの有病率の増加は、遺伝性がんの着実な成長を促進し、遺伝性がん検査市場の成長を促進しています。さらに、非侵襲性検査方法の需要の増加と、より質の高いヘルスケアと早期診断の需要の高まりは、市場成長の大きな機会です。さらに、遺伝性癌検査中に直面する倫理的な課題と市場プレーヤー間の競争の激化は、市場の成長にとって重要な課題です。

しかし、がん診断に関する厳格な規制と検査に伴う高額な費用が市場の成長を妨げる可能性があります。

Data Bridge Market Research は、アジア太平洋地域の遺伝性癌検査市場は、予測期間中に 14.0% の CAGR で成長し、2029 年までに 21 億 6,905 万米ドルに達すると予測しています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。

アジア太平洋地域の遺伝性癌検査市場の定義

遺伝性癌とは、遺伝的変異が受け継がれることで起こる癌のことです。特定の遺伝子の有害な変異は、癌のリスク増加と関連しています。遺伝子検査により、癌を発症する生涯リスクを推定できます。これは、遺伝子、染色体、またはタンパク質の変異を調べることで行うことができます。遺伝子検査は、いくつかの種類の癌で利用できます。これには、乳癌、卵巣癌、結腸癌、甲状腺癌、前立腺癌、膵臓癌、皮膚癌、肉腫、腎臓癌、胃癌が含まれます。多くの医学的研究により、一般的な癌の 5% から 10% が遺伝性であると考えられています。遺伝子検査は、人が有害な遺伝子変異を持っているかどうかを判断するために行われます。これらの検査は、まだ癌にかかっていない家族が、癌感受性の代替物を持っていることがわかっている家族と同じ変異を受け継いでいるかどうかを判断するのにも役立ちます。

アジア太平洋地域の遺伝性癌検査市場の動向

このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。    

ドライバー

• 遺伝性癌の発生率上昇

がんは、細胞の制御されない増殖から生じます。がんは、細胞の成長と分裂を制御する遺伝情報（遺伝子）の有害な変化（突然変異）によって発生し、細胞が効果的に機能できなくなります。

遺伝性癌の場合、個人は片方の親から変異した成長制御遺伝子のコピーを受け継ぎ、もう一方の親から同じ遺伝子の有効なコピーを受け継ぎます。変異した遺伝子は「癌感受性遺伝子」とも呼ばれます。この癌感受性遺伝子は受け継がれるため、体内のすべての細胞に存在しますが、遺伝子の有効なコピーによって各細胞は正常に機能します。ただし、変異によって細胞内の遺伝子の機能コピーが損傷すると、細胞は成長を制御できなくなり、癌化します。したがって、癌遺伝子を受け継いだ個人は、生涯に特定の癌を発症する可能性が非常に高くなります。

したがって、遺伝性癌の発生率の上昇により、遺伝性癌検査の需要が増加し、アジア太平洋地域の遺伝性癌検査市場の成長の原動力となる可能性があります。

•  高齢者人口の増加

がんは高齢患者の病気になり得ます。世界中で、高齢者人口が増加しています。高齢者の遺伝性がんのリスクはさらに高くなります。高齢者人口の増加は、アジア太平洋地域の遺伝性がん検査市場の供給改善につながる可能性があります。アジア太平洋地域の遺伝性がん検査市場では需要の急増が予想されています。 高齢化により人口構造の再分配が起こり 、医療の将来に影響を及ぼします。間違いなく、がんのリスクは年齢とともに指数関数的に増加します。

世界最大の完全な家族構成と医学的に確認された癌データベースを使用した遺伝性癌の発生率と関連リスクを含む調査では、遺伝性癌に罹患した親または親戚がいない人の兄弟姉妹から生まれた 8 ～ 20 歳の人口では、遺伝性癌の発生率が約 2 倍高くなっていました。小腸癌、精巣癌、甲状腺癌、骨癌のリスクは 5 ～ 8 倍高くなっていました。

したがって、高齢者人口における癌発症率の増加は、アジア太平洋地域の遺伝性癌検査市場の成長の原動力になると予想されます。

拘束

• 遺伝性癌検査の高額な費用

遺伝性癌の検査には、非常に高度な技術を駆使した製品が用いられます。これらの製品の開発には、開発企業による厳格な研究開発が必要です。そのため、手順と製品のコストは依然として高く、それに比例して検査コストも増加します。検査キットは、膨大なリソースを必要とし、高額な医師、輸送、高価な医薬品を必要とするため、高価です。

• さらに、がん検査にも検査手順が使用されています。しかし、このような手順は非常に高価であり、合併症や長期的な結果の悪化につながる可能性があります。

したがって、高度なモダリティとテクノロジー製品を使用したがん検査の高コストは、アジア太平洋地域の遺伝性がん検査市場の成長に対する大きな抑制要因となる可能性があります。

機会

• 市場参加者による戦略的取り組み

The rise in the Asia-Pacific hereditary cancer testing market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The surge in demand for hereditary cancer treatment is significantly increasing the demand for diagnostic testing methods. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.

These strategic initiatives, such as product launches, agreements, and business expansion by the major market players, will boost the market growth and are expected to act as an opportunity for the Asia-Pacific hereditary cancer testing market. The strategic initiatives are expected to aid in growth and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players are expected to act as an opportunity for growth in the Asia-Pacific hereditary cancer testing market.

Challenge

• Ethical Challenges Faced During Hereditary Cancer Testing

During hereditary cancer genetic testing, one of the significant ethical hindrances is health professionals' lack of basic knowledge about genetic testing and their lack of confidence in interpreting familial disease patterns. The challenge for healthcare providers is to provide sufficient information to support patient decision making-and evidence to support the reasoning behind any suggestions they might make.

The lack of reimbursement creates economic barriers to care. The process of hereditary cancer risk assessment and counseling is time-consuming, and it is unclear how best to document and bill for this service. Oncologists are often forced to navigate a potentially uncertain reimbursement environment for genetic testing, with various reimbursement policies among third-party payers.

Genetic testing for hereditary cancer elevates ethical matters, which can't be resolved with patients or their family members. The various aspects of ethical, cultural, and religious nature should not be a barrier to the act of hereditary cancer testing. All of these are issues to be solved. Therefore, ethical challenges during hereditary cancer testing are expected to challenge the market growth.

Post-COVID-19 Impact on Asia-Pacific Hereditary Cancer Testing Market

Many industries around the world have been disadvantaged over the past 18 months. This could be due to the major disruptions that their industrial and supply chain processes are experiencing due to various precautionary measures such as shutdowns and other restrictions that the facilities around the world have been following. The same places the Asia-Pacific hereditary cancer testing market. Also, consumption demand has subsequently decreased as people now have more opportunities to exclude non-essential expenses from their budgets as most people's overall finances have been severely affected by the boom. These aforementioned factors can be expected to burden the revenue margin of the Asia-Pacific hereditary cancer testing market during the forecast period.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the transplant diagnostics market.

Recent Developments

• In July 2022, Helio Genomics and its business partner, Fulgent Genetics (FLGT) has announced that the American Medical Association (AMA) issued a new Category I Current Procedural Terminology (CPT) Proprietary Laboratory Analyses code for HelioLiver and broader adoption of advanced innovative surveillance tests for liver cancer in the U.S. This has helped the company to expand their product portfolio.
• In March 2022, Illumina, Inc. introduced the n vitro diagnostic (IVD) kit, a cancer RNA sequencer. The launch resulted in expansion of the sequencing product line, followed by post market approval.It is depicted to show a linear market growth.

Asia-Pacific Hereditary Cancer Testing Market Scope

Asia-Pacific hereditary cancer testing market is segmented into test type, diagnosis type, technology, disease type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY TEST TYPE

• MULTI PANEL TEST
• SINGLE SITE GENETIC TEST

On the basis of test type, the Asia-Pacific hereditary cancer testing market is segmented into multi panel test and single site genetic test.

BY DIAGNOSIS TYPE

• BIOPSY
• IMAGING
• LAB TESTS

On the basis of diagnosis type, the Asia-Pacific hereditary cancer testing market is segmented into biopsy, imaging, and lab tests.

BY TECHNOLOGY

• SEQUENCING
• POLYMERASE CHAIN REACTION (PCR)
• MICROARRAY

On the basis of technology, the Asia-Pacific hereditary cancer testing market is segmented into sequencing, polymerase chain reaction (PCR), and microarray.

BY DISEASE TYPE

• HEREDITARY BREAST & OVARIAN CANCER SYNDROME
• COWDEN SYNDROME
• LYNCH SYNDROME
• HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROMES
• FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
• LI-FRAUMENI SYNDROME
• VON HIPPEL-LINDAU DISEASE
• MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROMES

On the basis of disease type, the Asia-Pacific hereditary cancer testing market is segmented into hereditary breast & ovarian cancer syndrome, cowden syndrome, lynch syndrome, hereditary leukemia and hematologic malignancies syndromes, familial adenomatous polyposis (FAP), li-fraumeni syndrome, vol-hippel lindau disease, multiple endocrine neoplasias (MEN) syndrome.

BY END USER

• HOSPITALS
• CLINICS
• LABORATORIES
• RADIOLOGY CENTERS 
• DIAGNOSTIC CENTERS
• OTHERS

On the basis of end user, the Asia-Pacific hereditary cancer testing market is segmented into hospitals, clinics, laboratories, radiology centers, diagnostic centers, and others.

BY DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES

On the basis of distribution channel, the Asia-Pacific hereditary cancer testing market is segmented into direct tender, retail sales.

Asia-Pacific Hereditary Cancer Testing Market Regional Analysis/Insights

The Asia-Pacific hereditary cancer testing market is analyzed and market size information is provided by test type, diagnosis type, technology, disease type, end user, and distribution channel.

The countries covered in this market report China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Philippines, Indonesia, and the rest of Asia-Pacific.

• In 2022, China is dominating due to its latest advanced technology and inventions for the diagnosis of cancer.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Hereditary Cancer Testing Market Share Analysis

Asia-Pacific hereditary cancer testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Asia-Pacific hereditary cancer testing market.

Some of the major players operating in the Asia-Pacific hereditary cancer testing market are Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.

Research Methodology: Asia-Pacific Hereditary Cancer Testing Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs Regional, and Vendor Share Analysis. Please request analyst call in case of further inquiry.

SKU-69432